Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Consensus Target Price from Analysts

Nektar Therapeutics (NASDAQ:NKTR) has received an average recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $2.33.

Several research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Rodman & Renshaw assumed coverage on Nektar Therapeutics in a research report on Friday, June 28th. They issued a “buy” rating and a $2.00 target price on the stock.

Institutional Trading of Nektar Therapeutics

Several large investors have recently made changes to their positions in NKTR. Victory Capital Management Inc. bought a new stake in shares of Nektar Therapeutics during the 2nd quarter worth about $29,000. Values First Advisors Inc. acquired a new position in shares of Nektar Therapeutics in the 2nd quarter worth approximately $56,000. State Board of Administration of Florida Retirement System acquired a new stake in Nektar Therapeutics during the 1st quarter valued at $63,000. SG Americas Securities LLC increased its holdings in Nektar Therapeutics by 63.0% during the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 28,338 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in Nektar Therapeutics during the 2nd quarter valued at $99,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Trading Up 1.6 %

NASDAQ:NKTR opened at $1.30 on Friday. The firm has a market capitalization of $239.23 million, a price-to-earnings ratio of -1.41 and a beta of 0.60. Nektar Therapeutics has a 1-year low of $0.41 and a 1-year high of $1.93. The business’s fifty day moving average price is $1.24 and its 200 day moving average price is $1.32.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The business had revenue of $23.49 million for the quarter, compared to analyst estimates of $17.24 million. Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same period in the previous year, the firm posted ($0.27) earnings per share. Equities analysts forecast that Nektar Therapeutics will post -0.85 earnings per share for the current year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.